Leadman(SZ:300289) Bei Jing Shang Bao·2025-11-13 11:47Core Viewpoint - Lidman plans to acquire 70% of Xiansheng Xiangrui for a cash consideration of 1.733 billion yuan, aiming to enter the high-barrier bioproducts industry and enhance growth opportunities [1] Group 1: Acquisition Details - The acquisition involves cash payments to Shanghai Baijia Hui, Hainan Baijia Hui, and Nanjing Baijia Rui for their combined stake in Xiansheng Xiangrui [1] - The total consideration for the acquisition is set at 1.733 billion yuan [1] Group 2: Strategic Rationale - By acquiring the controlling stake, the company can quickly penetrate the bioproducts industry, which has high barriers to entry and broader market prospects [1] - The acquisition is expected to significantly reduce the time required for product redevelopment and the establishment of market channels [1] - This move lowers the technical, talent, and management risks associated with entering a new business area [1] Group 3: Business Transformation - The company aims to achieve a business transformation by forming a dual main business model of "bioproducts + in vitro diagnostics" [1] - The strategy includes a dual-driven approach of independent research and external collaboration to explore new growth opportunities in innovative bioproducts such as vaccines [1] - This transformation is designed to enhance the company's growth ceiling and create favorable conditions for returning value to investors [1]